Used in research for potential treatment of schizophrenia and other psychiatric disorders. Acts as a selective agonist for metabotropic glutamate receptors, particularly mGlu2 and mGlu3, which modulates glutamate signaling in the brain. This mechanism offers an alternative to traditional dopamine-targeting antipsychotics, aiming to improve cognitive and negative symptoms with fewer side effects. Investigated for possible use in anxiety and depression, though clinical development has faced challenges due to variable efficacy results.